|
HHS' decision
to abruptly restrict the Food and Drug Administration's ability to require
premarket review of laboratory-developed tests (LDTs) through guidance and
other informal communications has industry players scrambling to figure out
how this impacts their diagnostic regulatory strategies.
|
Tuesday, September 1, 2020
Labs scramble after FDA loosens regulations on some tests
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment